BMT Survivor Study-2 (BMTSS-2)

BMT 幸存者研究 2 (BMTSS-2)

• 批准号: 10590723
• 负责人: SMITA BHATIA
• 金额: $ 126.69万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10590723
• 关键词: Acceleration; Address; Aftercare; Aging; Alabama; Android; Biological; Blood; Bone Marrow Transplantation; Cause of Death; Cessation of life; Chronic; Cities; Cohort Studies; Coronary Arteriosclerosis; DNA; Diabetes Mellitus; Diagnosis; Eligibility Determination; Enrollment; Epigenetic Process; Frequencies; Future; General Population; Genetic Determinism; Genetic Markers; Genetic Predisposition to Disease; Goals; Health; Health Insurance Portability and Accountability Act; Health behavior; Heart failure; Hematologic Neoplasms; High Prevalence; Hospital Costs; Hypertension; Incidence; Individual; Infrastructure; Intervention; Knowledge; Life; Lymphoma; Measures; Methodology; Minnesota; Modality; Morbidity - disease rate; Multiple Myeloma; Neoplasms; Outcome; Pathogenesis; Patient Self-Report; Patients; Peripheral Blood Stem Cell; Personal Satisfaction; Population; Predisposition; Premature Mortality; Premature aging syndrome; Progressive Disease; Radiation; Recurrence; Research; Resources; Retrospective cohort; Risk; Sample Size; Sampling Studies; Site; Source; Specimen; Survivors; Testing; Therapeutic; Time; Translational Research; Transplant Recipients; Transplantation; Umbilical Cord Blood; Universities; Validation; Vital Status; Work; chemotherapy; cohort; comorbidity; comparison group; conditioning; conventional therapy; demographics; design; epigenetic marker; experience; frailty; health care service utilization; high risk; human old age (65+); improved; indexing; leukemia; mortality; premature; prevent; procedure cost; relapse risk; repository; risk prediction model; stem cells; technology platform; transplant survivor; treatment risk; treatment strategy; trend; web app

In 2017, an estimated 1.3 million individuals were living with a hematologic malignancy (HM: leukemia, myeloma or lymphoma) in the US. Frontline use of systemic high-intensity chemotherapy with or without radiation characterizes the management of HM. Patients with progressive disease or at high risk of relapse are treated with even higher intensity chemotherapy/radiation and blood or marrow transplantation (BMT); indeed, BMT is often the only curative option for these patients. Steady improvements in outcome have resulted in a growing number of BMT-HM survivors – a population that is uniquely vulnerable to long-term chronic health conditions (CHCs) that are directly related to the high-intensity therapeutic exposures (e.g., subsequent neoplasms, heart failure). In 2000, we constructed a retrospective cohort of 2,333 BMT recipients (City of Hope [COH] or University of Minnesota [UMN]; BMT: 1974-1998), who had survived ≥2y (BMT Survivor Study [BMTSS]; R01 CA78938, Bhatia). While BMTSS has successfully described the high burden of morbidity, accelerated aging and premature mortality in BMT-HM patients, the modest sample size (n=2,333) and the older transplant era (1974-1998) has limited the potential for new discoveries, especially in the face of evolving treatment strategies. We propose a significant enhancement of the existing BMTSS cohort to now include 10,042 HM patients treated with BMT between 1974 and 2014 at COH, UMN or UAB (BMT-HM), as well as a frequency-matched cohort of 3000 HM patients treated with conventional therapy without BMT (non-BMT-HM). This enhanced infrastructure (BMTSS- 2) will be poised to determine the burden of morbidity borne by HM patients treated with or without BMT within the context of individual HM diagnoses, and to understand the pathogenesis of treatment-related health conditions in the setting of accelerated aging. The enhanced BMTSS-2 infrastructure will enable us to: i) understand the long-term risk of health conditions experienced by HM patients treated with and without BMT; ii) determine the association between treatment exposures and health conditions; iii) determine trends in health conditions with changes in treatment strategies; iv) identify interactions between preventable modifiers (comorbidities, health behaviors) and treatment exposures when determining risk of health conditions; v) study the pathogenesis of treatment-related health conditions in the setting of accelerated aging, using genetic markers for susceptibility and epigenetic markers for the association of the health conditions with aging; vi) use HIPAA- compliant technology platform compatible with iOS/Android/iPad/Web-based applications to educate HM patients and measure health behaviors in real time. This is the largest and most comprehensive attempt at examining the health and wellbeing of HM patients treated with and without BMT. The overarching goal is to use BMTSS-2 for translational research along two tracks: A) develop risk prediction models to identify HM recipients at highest risk of treatment-related health conditions; and B) among those identified to be at highest risk, design and test targeted interventions to prevent/ ameliorate these debilitating chronic health conditions.

2017年，估计有130万人患有血液恶性肿瘤（HM：白血病、骨髓瘤）

项目成果

Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.

自体血液或骨髓移植幸存者的静脉血栓栓塞：血液或骨髓移植幸存者研究报告。

• DOI: 10.1016/j.bbmt.2019.06.032
• 发表时间: 2019
• 期刊: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
• 作者: Gangaraju,Radhika;Chen,Yanjun;Hageman,Lindsey;Wu,Jessica;Francisco,Liton;Battles,Kevin;Kung,Michelle;Ness,Emily;Parman,Mariel;Weisdorf,DanielJ;Forman,StephenJ;Arora,Mukta;Armenian,SaroH;Bhatia,Smita
• 通讯作者: Bhatia,Smita

Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.

在先前的酪氨酸激酶抑制剂暴露的背景下，慢性粒细胞性白血病的骨髓移植后的晚期死亡率：血液或骨髓移植幸存者研究（BMTSS）报告。

• DOI: 10.1002/cncr.32443
• 发表时间: 2019-11-15
• 期刊: Cancer
• 影响因子: 6.2

Neighborhood disadvantage, health status, and health care utilization after blood or marrow transplant: BMTSS report.

• DOI: 10.1182/bloodadvances.2022007548
• 发表时间: 2023-02-14
• 期刊: BLOOD ADVANCES
• 影响因子: 7.5
• 作者: Wolfson, Julie A.;Bhatia, Smita;Hageman, Lindsey;Ross, E. S.;Balas, Nora;Bosworth, Alysia;Te, Hok Sreng;Francisco, Liton;Funk, Erin;Hicks, Jessica;Landier, Wendy;Wu, Jessica;Siler, Arianna;Lim, Shawn;Wong, F. Lennie;Armenian, Saro H.;Arora, Mukta;Aswani, Monica S.
• 通讯作者: Aswani, Monica S.

Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model.

• DOI: 10.1182/bloodadvances.2021004341
• 发表时间: 2021-10-26
• 期刊: Blood advances
• 影响因子: 7.5
• 作者: Gangaraju R;Chen Y;Hageman L;Wu J;Francisco L;Kung M;Weisdorf DJ;Forman SJ;Arora M;Armenian SH;Bhatia S
• 通讯作者: Bhatia S

Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant.

血液或骨髓移植后胃肠道恶性肿瘤。

• DOI: 10.1001/jamaoncol.2022.6569
• 发表时间: 2023
• 期刊: JAMA oncology
• 影响因子: 28.4
• 作者: McDonald,Andrew;Dai,Chen;Meng,Qingrui;Hageman,Lindsey;Richman,Joshua;Wu,Jessica;Francisco,Liton;Ross,Elizabeth;Balas,Nora;Bosworth,Alysia;Te,HokSreng;Wong,FLennie;Landier,Wendy;Salzman,Donna;Bhatia,Ravi;Weisdorf,DanielJ